This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
Other titles
the names this measure carries besides the one at the top of this page, each with the record's own label for it. The collection includes titles given to parts of a bill as well as to the whole.
To mitigate the effects of the COVID-19 pandemic on incentives under the Federal Food, Drug, and Cosmetic Act for the development of orphan drugs, and for other purposes.Official Title as Introduced
HouseReferred to the House Committee on Energy and Commerce.
Documents
Everything Congress printed about this measure. A bill is reprinted each time it changes, the Congressional Research Service summarizes each version, and the committee that reports a bill files its own written account of it.